Opinion

Video

Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy response, BTK C481 mutation status, comorbidities, drug interaction profiles, dosing convenience, and adverse effect considerations, with noncovalent inhibitors offering particular benefit for those with BTK mutations or intolerance to covalent agents.

Video content above is prompted by the following:

  • What key factors influence your decision when selecting among the available BTK inhibitors for patients with R/R CLL?
  • What clinical or molecular features help identify patients with R/R CLL who are most likely to benefit from noncovalent BTK inhibitors compared with covalent BTK inhibitors?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
Dr Ibrahim Aldoss
1 expert is featured in this series.
Miriam Freimer, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo